UNSPSC 51284909: Phenazopyridine/sulfisoxazole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM650. This VA Drug Class (AM650) classifies this compound as belonging to the group SULFONAMIDE/RELATED ANTIMICROBIALS.

UNSPSC 51284909 Phenazopyridine/sulfisoxazole is a Commodity code that shows minimal alignment with actual state and local procurement activity posted in recent solicitations. The code's nominal scope—a specific urinary analgesic and sulfonamide antibiotic combination—does not match the pharmaceutical and medical supply purchases appearing under this code number in the market. Recent opportunities posted under this code include emergency-response medical supplies (respiratory equipment, cardiac monitoring electrodes, bandaging materials), generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, direct-to-manufacturer prescription programs, and opioid-reversal agents, none of which are phenazopyridine/sulfisoxazole formulations. State and local buying under this code reflects public health and emergency services demand: county and city health departments, fire departments, and state health agencies are the typical issuing bodies, often operating through cooperative purchasing vehicles to extend buying power across multiple jurisdictions.

Geographic activity is concentrated in Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving participating state and local facilities across multiple states including Oregon. Recent representative opportunities include Seminole County, Florida's IFB (due July 26, 2023) for naloxone and drug deactivation systems with annual volumes of 1,900 units of naloxone and 800 systems; the City of Tampa's competitive sealed-bid solicitation (due March 13, 2026, estimated value $700,000) for medical and first aid supplies for the Tampa Fire Department Rescue Division, designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount; and MMCAP's RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers. The Texas Health and Human Services Commission also posted an RFI (April 3, 2026) exploring direct-to-manufacturer prescription programs. The code's scope-to-actual-procurement mismatch suggests either a data-entry error in the original taxonomic assignment or outdated code usage by issuing bodies; buyers pursuing this code should verify the actual goods or services being solicited in each individual opportunity rather than relying on the nominal code definition.